Cardiac Imaging

While cardiac ultrasound is the widely used imaging modality for heart assessments, computed tomography (CT), magnetic resonance imaging (MRI) and nuclear imaging are also used and are often complimentary, each offering specific details about the heart other modalities cannot. For this reason the clinical question being asked often determines the imaging test that will be used.

RSS icon

Pathway Medical makes executive moves

Arterial disease device developer Pathway Medical of Redmond, Wash.,has appointed Paul Buckman to its board of directors and hired JohnYaholkovsky as its vice president of manufacturing.

Micrus acquires revascularization technology

Micrus Endovascular, a Sunnyvale, Calif.-based developer of cerebralvascular devices used in interventional radiology, reported that it hassigned a letter of intent to acquire the rights to a revascularizationtechnology for the treatment of ischemic stroke from ReVascTechnologies, a start-up company affiliated with the Cleveland ClinicFoundation.

SonoSite acquires LumenVu

SonoSite, a Bothell, Wash.-based developer of hand-carried ultrasounddevices, has acquired LumenVu, a privately held, development-stagecompany based in Philadelphia.

Appling named AngioDynamics VP

Interventional radiology device developer AngioDynamics of Queensbury,N.Y., has promoted its vice president of research, William Appling, tothe position of senior vice president of research and development,effective immediately.

Neoprobe bolsters board

Oncology and cardiovascular surgical and diagnostic product developerNeoprobe has appointed Dr. Owen Johnson to its board of directors.

AngioDynamics posts Q4 uptick, year-end loss

Interventional device developer AngioDynamics of Queensbury, N.Y.,reported a double-digit increase in sales and net income for its 2007fiscal fourth quarter (end-June 2).

Study: Rapid growth for North American contrast media market

The North American contrast media market is experiencing rapid growthin several segments, spurred by the aging population and increasedincidence of diseases, especially cardiovascular.

Draxis seeks DraxImage Sestamibi clearance in Europe

DraxImage, the radiopharmaceutical division of Mississauga,Ontario-based Draxis Health, has filed for marketing clearance for itsDraxImage Sestamibi with European regulatory authorities.

Displaying 1617 - 1624 of 1765

Around the web

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

Cardiovascular Business
FDA clears AI tool that flags signs of heart disease in chest CT scans

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup